GFAP antibody (Intracellular) (Atto 647N)
Quick Overview for GFAP antibody (Intracellular) (Atto 647N) (ABIN7582030)
Target
See all GFAP AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 27-39, Intracellular
-
Purpose
- A Rabbit Polyclonal Antibody to GFAP conjugated to the fluorescent dye ATTO Fluor-647N
-
Sequence
- (C)RHLGTIPRLS LSR
-
Specificity
- Intracellular, cytoplasm
-
Predicted Reactivity
- Mouse - 10,13 amino acid residues identical The antibody will not recognize human GFAP
-
Characteristics
- Anti-GFAP Antibody (ABIN7043217, ABIN7044273 and ABIN7044274) is a highly specific antibody directed against an epitope of the rat GFAP protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize GFAP from rat and mouse samples. The antibody will not recognize human GFAP. Anti-GFAP-ATTO Fluor-647N Antibody (ABIN7043217, ABIN7044273 and ABIN7044274-FRN) is directly conjugated to the ATTO Fluor-647N fluorophore. This conjugated antibody has been developed to be used in immunofluorescent applications such as multicolor immunohistochemistry and immunocytochemistry. It has been designed to recognize GFAP from mouse and rat samples. The antibody will not recognize human GFAP. ATTO Fluor 647N belongs to a new generation of fluorescent labels for the red spectral region. Characteristic features of the label are strong absorption, high fluorescence quantum yield, high thermal and photo-stability, and exceptionally high stability towards atmospheric ozone. Thus ATTO Fluor 647N is highly suitable for single-molecule detection applications and super-resolution microscopy techniques such as Structured Illumination Microscopy (SIM), Stimulated Emission Depletion (STED), etc.
-
Purification
- Affinity purified on immobilized antigen.
-
Immunogen
- (C)RHLGTIPRLSLSR, corresponding to amino acid residues 27-39 of rat Glial fibrillary acidic protein
-
Isotype
- IgG
-
-
-
-
Application Notes
-
Antigen preadsorption control: 1 μg peptide per 1 μg antibody
Application Dilutions Immunohistochemistry paraffin embedded sections ihc: 1:80-1:100
Application Dilutions Western blot wb: N/A
-
Comment
-
Negative Control: (ABIN7582045)
Blocking Peptide: (ABIN7235599)
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- 50 μL double distilled water (DDW).
-
Concentration
- 1 mg/mL
-
Buffer
- PBS pH 7.4, 1 % BSA with 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
-
Storage before reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
Storage after reconstitution: The reconstituted solution can be stored at 4°C, protected from the light, for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).
-
-
- GFAP (Glial Fibrillary Acidic Protein (GFAP))
-
Alternative Name
- GFAP
-
Background
- Glial fibrillary acidic protein,Glial fibrillary acidic protein (GFAP) is a key intermediate filament (IF) III protein responsible for maintaining the mechanical strength of glia cells by supporting their cytoskeleton structure. GFAP is expressed in astrocytes in the CNS, non-myelinating Schwann cells in the PNS, and enteric glial cells1.GFAP has a structural organization that is typical to class III IF proteins: it has a head, rod, and tail domains. The N-terminal head domain is important for filament formation and the C-terminal domain is important for oligomerization2.GFAP is encoded by a single gene mapped to human chromosome 17q21. To date, 10 isoforms/splice variants have been identified. GFAP is tightly regulated: both at mRNA transcription level and by phosphorylation and other post-translational modifications. A number of growth factors such as CNTF, FGF and TGF-β can induce GFAP gene transcription activation leading to increased GFAP protein levels3.Single nucleotide polymorphism (SNP) in GFAP results in the formation of Rosenthal fibers that cause Alexander Disease, hence, GFAP is a potential drug target for the treatment of this disease. A number of GFAP mutations were found in the coding and in the promoter regions of Alexander disease patients4.GFAP gene activation and protein induction appear to play a critical role in astroglia cell activation (astrogliosis) following CNS injuries and neurodegeneration. GFAP protein and its breakdown products are rapidly released into biofluids following traumatic brain and spinal cord injuries and stroke, making them strong candidate biomarkers for such neurological disorders5.
-
Gene ID
- 24387
-
UniProt
- P47819
Target
-